Submicron nucleocapsid microsphere material capable of releasing active factors on time and preparation method of submicron nucleocapsid microsphere material
A technology that releases active core-shell microspheres, applied in medical science, prostheses, etc., can solve the problems that the size effect of core-shell microspheres is difficult to meet clinical transformation applications, and the timing synergy between osteogenesis and angiogenesis cannot be obtained. Benefits of clinical transformation application, strong controllability, simple preparation and processing methods
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0026] (1) Weigh 0.4g poly-D,L-lactic acid (PDLLA), add 10mL trifluoroethanol solution to swell at room temperature for 1h, and then stir at 37°C for 24h to form a uniform shell solution of 2% w / v. Weigh 0.2 g of PLGA, add 10 mL of trifluoroethanol solution to swell at room temperature for 1 h, and then stir at 37° C. for 24 h to form a 4% w / v uniform core layer solution.
[0027] (2) Dissolve VEGF and BMP‐2 growth factors in ultrapure water respectively, add VEGF solution to the shell layer solution at a ratio of 10nm / ml, and add BMP‐2 solution to the core layer solution at a ratio of 100nm / ml , respectively stirred for 10 min to form a uniform and stable core and shell solution.
[0028] (3) Inject the core and shell solutions obtained in step (2) into 20mL medical syringes respectively, and place them in a coaxial electrostatic spray device to spray microspheres with a spray voltage of 15kV, a total flow rate of 0.8ml / h, and a core-shell flow rate ratio of 1. : 3, the rece...
Embodiment 2
[0032] (1) Prepare 1% w / v PDLLA trifluoroethanol core layer solution, swell at room temperature for 1 hour, and stir at 37°C for 24 hours; prepare 3% w / v PLGA trifluoroethanol core layer solution, swell at room temperature for 1 hour, and stir at 37°C 24h.
[0033] (2) Dissolve VEGF and BMP‐2 growth factors in ultrapure water respectively, add VEGF solution to the nuclear layer solution at a ratio of 10nm / ml, and add BMP‐2 solution to the nuclear layer solution at a ratio of 100nm / ml , respectively stirred for 10 min to form a uniform and stable core and core layer solution.
[0034] (3) Inject the core and layer solutions obtained in step (2) into 20mL medical syringes respectively, place them in a coaxial electrostatic spraying device to spray microspheres, the spraying voltage is 15kV, the total flow rate is 0.8ml / h, and the core-shell flow rate ratio is 1: 4. The receiving board distance is 20cm.
[0035] (4) Dry the product obtained in step (3) in a vacuum freeze dryer ...
Embodiment 3
[0038] (1) Prepare 1% w / v PDLLA trifluoroethanol core layer solution, swell at room temperature for 1 hour, and stir at 37°C for 24 hours; prepare 3% w / v PLGA trifluoroethanol core layer solution, swell at room temperature for 1 hour, and stir at 37°C 24h.
[0039] (2) Dissolve BMP-2 and VEGF growth factors in ultrapure water respectively, add BMP-2 solution to the nuclear layer solution at a ratio of 100nm / ml, and add VEGF solution to the nuclear layer solution at a ratio of 10nm / ml , respectively stirred for 10 min to form a uniform and stable core and core layer solution.
[0040] (3) Inject the core and layer solutions obtained in step (2) into 20mL medical syringes respectively, place them in a coaxial electrostatic spraying device to spray microspheres, the spraying voltage is 15kV, the total flow rate is 0.8ml / h, and the core-shell flow rate ratio is 1: 2.
[0041] (4) Dry the product obtained in step (3) in a vacuum freeze dryer for 24 hours, and store it sealed at -...
PUM
| Property | Measurement | Unit |
|---|---|---|
| diameter | aaaaa | aaaaa |
| size | aaaaa | aaaaa |
| size | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More